Posted by: Audrey Erbes | October 28, 2012

IPO Window Opening plus Events and Jobs

IPO Window Is Opening

The sands are shifting again with respect to biotech IPOs. The 2012 class as of October saw 12 companies IPO. This is certainly an improvement after the drought of the previous 4 years. One has to wait to see how the stock price holds up through the “lock out” phase before one can claim true success but evidence indicates there’s a balance developing for IPOs—not cold any longer and not overheated. You can find the list of firms included in IPO class this year in a blog by Luke Timmerman, the national biotech editor at Xconomy.

Despite a dramatic shrinkage in VC firms by more than half from 2000 until 2010, there are still some active firms investing in other than just late stage companies and making this and future IPO activity possible. We have heard that one-half to two-thirds of all the people who make a living in biotech venture capital are on their way out, yet some VCs remain who claim there’s still money for the best ideas and companies. Science continues to proliferate and those VC firms that survive can cherry pick the winners just as earlier VCs who stuck it out in the late 90s did.

Perhaps as some VCs told me, the “amateurs” that gravitated  to the life science sector after the crash have left and now the experienced VCs are running the investments. In a July 2012 blog Luke Timmerman provided a list of VC firms that were still active in investing.He selection criteria was those firms investing in at least 4 early-stage life science companies (biotech and medical devices) and having placed $12 million in the sector during the 12-month period that ended March 31, 2012.

Upcoming Meetings This Week

  • BioCentury TV Today, See new program Webcast Starting Sunday, Oct. 28, 2012, Available anytime starting at 9:00 a.m. EDT; Topic: “Creating Hope: Cures for Kids;” Speakers: Nancy Goodman, founder of Kids v Cancer and leader of the movement that prompted Congress to pass the Creating Hope Act, which rewards biopharma companies when they develop drugs for rare pediatric diseases.; Megan O’Boyle, a director of the Phelan-McDermid Syndrome Foundation, who created a patient registry and in one year collected data from almost half of all the children diagnosed with this neurogenetic disorder; and Kristin Smedley, a founder of the CRB1 Fund, which is dedicated to raising money and recruiting scientists to apply genetic research in the search for a cure for congenital retinal blindness.
  • El Camino Hospital, Monday Evening, Oct. 29, 2012; Topic: “Breast Health: Innovations and Advancements;” Panelists:Senator Joe Simitian , 11th District, California State Senate, Champion of Senate Bill 1538, Dense Breast Tissue Notification, recently signed into law by Governor Brown; Peter Naruns, Md, Chair, High Risk Breast Program, El Camino Hospital, Lead, Breast Tumor Board, El Camino Hospital Cancer Center Breast Surgeon; Imtiaz Qureshi, Md, Medical Director, Breast Health Center, El Camino Hospital, Radiologist; and Katherine Sutherland, Md, Medical Director, Genomic Medicine Institute, El Camino Hospital Ob/Gyn; Nandini Tandon, PhD, El Camino Hospital Board Member, U-Systems Board Member, will serve as event emcee.
  • Bio2Device Group, Tuesday Morning, Oct. 30, 2012; Topic: “Integrating Reimbursement into Early Stage Diagnostic Development,” Speaker: Stanley Skrzypczak, M.S., M.B.A., Senior Director, Commercial Development, Genomic Health
  • Deloitte Recap LLC, Tuesday Morning, Oct. 30, 2012; Topic: Deloitte Recap Webinar: Ways to Determine the Optimal Time to Partner
  • Genetic Engineering and Biotechnology News, Thursday Morning, Nov. 1, 2012; Topic: “Learning from History: Making Biosimilars a Reality;” Panelists: Mark McCamish, M.D., Ph.D., Global Head ofBiopharmaceutical Development, Sandoz Biopharmaceuticals; Graham Jones, Ph.D., Chair, Department ofChemistry & Chemical Biology, Northeastern University; Marie Rock, Ph.D., Senior Scientific Directorof Large Molecule Bioanalysis,WIL Research; John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News, will be the host of this webinar.
  • BayBio Pantheon Ceremony, Thursday, Nov. 1, 2012; Event: 2012 Pantheon Ceremony Presenting DiNA Awards
  • Real Endpoints Symposium, Thursday and Friday, Nov. 1-2, 2012; Topic: “DISRUPTORS: How They’re Changing Healthcare Reimbursement,” Postponed until 2013 due to SANDY, the big storm hitting the East Coast this week
  • Medtech Frontiers, Thursday Evening, Nov. 1, 2012; Topic: “mHealth: Hype, Disillusionment, or the Future of Healthcare?”Speaker: Marta Gaia Zanchi
  • CACO, Friday, Nov. 2, 2012; Topic: “Analytical Development and Drug Quality Control;” Speakers: M.Dong, K.Zhang,C.Gu & J.Pellett (Genentech), D.Prudhomme(Gilead),D.Toman(Elan),Y.Wang(FDA)

You can find the full list Audrey’s Picks through the end of December with details as well as this week’s Jobs That Crossed My Desk by right clicking on the highlighted titles. The latter includes new listings this past week plus the prior two weeks.

Vote early and beat the rush! Also Happy Halloween!



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s


%d bloggers like this: